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Abstract: Background and objectives: Citrullus colocynthis (CC), known as bitter apple, is used to treat
diabetes in Iranian traditional medicine. The aim of this study is to evaluate the anti-inflammatory
and analgesic activities of CC cream in rats. Materials and Methods: The carrageenan-induced edema
in a rat hind paw was carried out to evaluate the topical anti-inflammatory effect of the CC fruit
extract cream (2–8%) and the tissue levels of IL-6 and TNF-α were estimated by using a commercial
ELISA kit. The topical antinociceptive activity of CC cream (2–8%) was evaluated in the rat formalin
test. To determine the role of opioid receptors in the local antinociceptive effect of the CC cream,
naloxone (20 µg/paw, i.pl.), a non-selective opioid antagonist, was used. Results: The results showed
that the CC cream (2–8%) dose-dependently reduced the carrageenan-induced paw edema and
reversed the changes in the level of TNF-α and IL-6 due to carrageenan-induced edema (p < 0.01).
The anti-inflammatory effect of CC cream 8% was comparable to that of hydrocortisone ointment 1%.
Furthermore, the application of CC cream (2–8%) dose-dependently inhibited both first and second
phases of the formalin test (p < 0.05). The antinociceptive effect of the CC cream (8%) was comparable
to that of methyl salicylate cream 30%. Moreover, the administration of naloxone significantly
reversed the topical antinociceptive effect of the CC cream (p < 0.05). Conclusions: For the first time,
this study indicated that the topical application of CC cream possesses significant anti-inflammatory
and antinociceptive activities in animal models, which were probably mediated by opioid receptors
and the suppression of pro-inflammatory cytokines (TNF-α and IL-6). Thus, the CC cream can be
used to treat inflammatory pain and inflammatory diseases.
Keywords: Citrullus colocynthis; cream; antinociceptive; anti-inflammatory; rat
1. Introduction
Pain and inflammation are the most common and main symptoms of many diseases. Inflammation
as the most important response of a damaged tissue induces a variety of hostile stimuli such as
infections, toxic chemical agents, and physical damage resulting in redness, edema, heat, and pain [1].
Many studies have indicated that inflammatory reactions are implicated in the progression of several
disorders, such as aging [1] rheumatoid arthritis [2], skin inflammation [3], and cardiovascular
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dysfunction [4]. The tissue inflammation is mediated by infiltration and activation of leukocytes
into the damaged region and the release of pro-inflammatory mediators, including tumor necrosis
factor (TNF), interleukin 6 (IL-6), and IL-1β [5]. Although non-steroidal anti-inflammatory drugs and
opioids are widely used in the treatment of inflammatory diseases and pain, these drugs have a variety
of side effects. The most important side effect of opioids is tolerance and the chronic administration of
NSAIDs leads to gastrointestinal bleeding [6]. Therefore, research to identify anti-inflammatory and
analgesic compounds with fewer side effects and more efficacy is necessary. Complementary to this,
herbal compounds are one of the most important sources for the discovery of new drugs with a high
safety margin [7].
Citrullus colocynthis (CC), known as bitter apple, is used topically to treat diabetes in Iranian
traditional medicine. CC grows extensively in the center, south, and east of Iran. Most of the
therapeutic effects of this plant are related to its fruit [8]. Studies have shown that the fruit of CC has
a variety of pharmacological effects, including anti-inflammatory [9], analgesic [10], anticancer [11],
hypolipidemia [12], immunostimulating [13], antioxidant [14], and antidiabetic [5]. The most important
active ingredients of this plant are glycosides, flavonoids, alkaloids, monoterpenes, phenolic acids,
triterpenoid, carbohydrates, fatty acids, and essential oils [2,5,15–18].
Previous studies have showed the systemic antinociceptive and anti-inflammatory effects of
C. colocynthis extract, but its exact mechanisms have not been identified. Heidary et al. (2015),
showed that C. colocynthis fruit extract possesses analgesic activity in patients with painful diabetic
polyneuropathy [8]. Marzouk et al. (2010) showed that the oral administration of C. colocynthis fruit
extract decreased paw edema induced by 1% carrageenan [2]. The protective effect of C. colocynthis
has been attributed to the suppression of pro-inflammatory release, inhibition of COX-2 expression,
and its antioxidant activity [5,10,19].
Growing evidence that systemic uses of CC cause severe adverse effects such as acute
rectorrhagia, liver intoxication, abortifacient, cardio-depressant, and emetic effects, can be seen
in the literature [15,20]. For instance, Javadzadeh et al. (2013) reported that the consumption
of CC led to tenesmus and bloody diarrhea. The intestinal damage and rectorrhagia have been
attributed to the membranolytic effect of CC constituents [21]. In addition, Dehghani et al. (2006),
have shown that CC extract (>100 mg/kg) induced hepatic intoxication, which was accompanied
by hepatic fibrosis and necrosis [22]. In addition, toxic doses of CC (600–1000 mg) lead to tenesmus,
hematochezia, and nephrosis. A lethal dosage (>2 g) caused paralysis, circulatory collapse, and finally,
death [15]. In sum, it is critical to save the beneficial effects of CC and limit its adverse effects with
appropriate approaches.
The topical administration of drugs has many benefits, including optimizing the concentration of
the drug in the position, reducing systemic drug levels, reducing systemic side effects, and reducing
drug interactions. Currently, the topical form of anti-inflammatory drugs, local anesthetics,
and analgesics is widely used by patients [23].
Although previous studies have shown the anti-inflammatory and analgesic activity of CC extract,
its systemic use is limited due to a very bitter taste and high risk of gastrointestinal bleeding [21].
So, for the first time, in this study, we evaluated the anti-inflammatory and antinociceptive activity of
the topical application of CC extract and its underlying mechanisms in animal models.
2. Materials and Methods
2.1. Chemicals
Carrageenan and formalin were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Hydrocortisone ointment 1%, methyl salicylate 30%, naloxone hydrochloride, and morphine
sulfate (5H2O) were purchased from Iran Darou, Sobhan Darou Pharmaceutical Co. and Temad
Pharmaceutical Co. (Tehran, Iran), respectively. ELISA kits for the determination of TNF-α and IL-6
were provided by Diaclone (Besancon, France). Solvents for extraction were of commercial grade.
Medicina 2018, 54, 51 3 of 11
2.2. Plant Material
C. colocynthis fruits used in this experiment were collected from Dezful, Khuzestan province, Iran
(48◦32′45.591′′ N; 32◦18′8.702′′ E) in April 2016. These fruits were identified by the Pharmacognosy
Department of Ahvaz Jundishapur University of Medical Science (AJUMS, Ahvaz, Iran), Ahvaz, Iran
and were deposited at the Herbarium of the AJUMS under the label A150740102FP.
2.3. Hydroalcoholic Extraction
After removing the seeds, dried fruits at an ambient temperature were powdered by an electric
mill. The powder was macerated with 70% aqueous ethanol at room temperature for 72 h by stirring
daily. After filtration, the resulting extract was evaporated (under temperature below 40 ◦C and
reduced pressure) to remove the solvent, and it was then lyophilized and stored at −20 ◦C until the
beginning of the experiments.
2.4. Formulation of Topical Preparation
The cream base that consists of the oil phase and the aqueous phase was prepared according to
the following procedure. First, the oil phase components containing 15 g of spermaceti and 60 g of
liquid paraffin were weighed, and were then placed in a container and heated to 75 ◦C in a bain-marie
to thoroughly melt them, and a smooth solution was achieved. The aqueous phase contained 25 g
of deionized distilled water at 75 ◦C in a bain-marie, to which 0.15 g of methylparaben was added
as a preservative, and after dissolution, 1 g of borax was added as an emulsifier and then mixed.
After both the two phases were cooled, the aqueous phase was added to the oil phase and mixed
slowly. The stirring was continued until the cream base was obtained at room temperature. After
neutralization, the cream base of NaOH (pH 6.2) was formed, and the lyophilized extract of the CC
was dissolved in a small amount of ethanol and added to the cream base to obtain ratios (w/w) of 2
and 4% and 8%.
2.5. Inflammation and Nociception Assessment
2.5.1. Animal
Seventy-two male Sprague-Dawley rats (130–170 g) were obtained from the animal house and
research center of AJUMS, Ahvaz, Iran. They were fed with rodent laboratory chow ad libitum
and had free access to water. The experimental design was approved by the Institutional Animal
Ethical Committee of Ahvaz Jundishapur University of Medical Science (IR.AJUMS.REC.1395.649)
and conducted according to the NIH Guide for Care and Use of Laboratory Animals.
2.5.2. Carrageenan-Induced Acute Inflammatory Model
The carrageenan-induced edema in a rat hind paw was carried out to evaluate the
topical anti-inflammatory effect of the preparations [24]. The solution of carrageenan 1% in
normal saline was prepared freshly, immediately before experiments. Edema was induced
by an intraplantar injection of 100 µL carrageenan solution into the right-hind paws of each
animal of all the groups, except for group I. Hydrocortisone ointment 1% was used as an
anti-inflammatory reference drug. The rats were randomly assigned to the following groups:
I (saline + cream base) as the saline group, II (carrageenan + cream base) as the negative
control, III (carrageenan + CC 2%), IV (carrageenan + CC 4%), V (carrageenan + CC 8%), and
VI (carrageenan + Hydrocortisone ointment 1%) as the positive control. All preparations in an amount
of 0.3 g were used half an hour before the injection of carrageenan (1%, 100 µL, intraplantar injection)
in the plantar surface of the right hind paw and it was gently rubbed 50 times with the index finger.
Hydrocortisone ointment 1% and the cream base were applied in a similar way. The edema value
was measured by a plethysmometer (Ugo Basile, Milan, Italy) prior to the intraplantar injection
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of carrageenan and at 1, 2, 3, and 4 h post-carrageenan injection. At the end of the experiment,
the rats were euthanized and subplantar tissue of the carrageenan-injected paw was dissected. All
tissue samples were weighed and homogenized with radioimmune precipitation assay (RIPA) buffer,
and after that, the homogenates were centrifuged at 3000 rpm for 10 min at 4 ◦C and the supernatants
were maintained at −80 ◦C for cytokines assessment.
2.5.3. Formalin Test
To evaluate the antinociceptive effect of the cream, the formalin test was used according to the
method described by Dubuisson and Dennis (1977) [25]. On the plantar surface of the right hind paw,
0.3 g of cream containing 2–8% of CC was applied and gently rubbed 50 times with the index finger.
Cream base and methyl salicylate 30% were used as the control and reference drug, respectively. Thirty
minutes later, 50 µL of 2.5% formalin was administrated by an intraplantar injection into the dorsal
right hind paw of rats. The number of flinching events of the paw was monitored between 0–5 min
(first phase) and 15–60 min (second phase) after the injection of formalin. To evaluate the local effect of
cream, it was administrated on the right hind paw and 30 min later, formalin was injected into the left
hind paw then, and the flinching number was recorded.
2.5.4. Involvement of Opioid Receptors in the Peripheral Antinociceptive Effect of CC Cream
To determine the role of opioid receptors in the local antinociceptive effect of the CC cream,
naloxone, a non-selective opioid antagonist, was used. Naloxone (20 µg/paw, i.pl.) was injected
30 min before the formalin injection [26].
2.6. Cytokine Assay
The tissue levels of IL-6 and TNF-α were estimated by using the commercial ELISA kit (Diaclone
Research, Besancon, France) according to the manufacturer’s recommendations. The absorbance of all
samples was read at 450 nm. The levels of tissue cytokines were expressed as pg/g paw tissue.
2.7. Skin Irritation Test
Twelve rats were divided into two groups (six rats in each group), including control and test
groups. The hair was shaved behind the animal and the rats were kept in separate cages. For seven
days and once a day, 50 mg of cream was placed on a 4 cm2 area. The area was covered with a cotton
bandage, and any sensitivities were assessed and graded (A. No edema, B. Slight erythema, C. up to
severe edema, D. Moderate erythema, E. Severe erythema) [27].
2.8. Statistical Analysis
Data were expressed as mean ± SD. Comparisons between means of different groups were
carried out using one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test and
repeated measures ANOVA followed by Dunnett’s test. The level of significance was taken as
p < 0.05. GraphPad Prism v. 5 (GraphPad software Inc., La Jolla, CA, USA) was used to carry out all
statistical tests.
3. Results
3.1. Effect of Topical CC Cream on Carrageenan-Induced Inflammation
Repeated measures ANOVA analysis of paw volume indicated that the carrageenan injection
significantly increased the paw volume compared with the basal volume before the carrageenan
injection (p < 0.001). The topical preparation of CC 2–8% significantly decreased the paw volume
compared with the carrageenan group during the experiment, in a dose-dependent manner (effect of
group p < 0.0001, of time p = 0.0001 and interaction effect p < 0.0001) (Figure 1).
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Figure 1. Change in paw edema at t = 1, 2, 3, and 4 h after carrageenan administration (0.1 mL of 1%, 
intraplantar injection). Data are expressed as mean ± SD. Car: carrageenan 1%, CC: C. colocynthis 
cream. (n = 6). * p < 0.05 vs. basal volume before carrageenan injection and # p < 0.05 vs. carrageenan 
group. Repeated measures ANOVA followed by Dunnett’s test. 
3.2. Effect of Topical CC Cream on Cytokines Level 
As shown in Figure 2A,B, carrageenan significantly increased the TNF-α and IL-6 concentration 
in the hind paw 4 h post-carrageenan injection compared with the saline group. The topical 
administration of CC cream (2–8%) significantly reversed the changes in the level of TNF-α and IL-6 
due to carrageenan-induced edema, in a dose-dependent manner (p < 0.01). 
 
Figure 2. Effect of topical administration of C. colocynthis (CC) cream (2–8%) on the levels of TNF-α 
(A) and IL-6 (B) in rats 4 h after carrageenan-induced hind paw edema (0.1 mL, 1%, intraplantar 
Figure 1. Change in paw edema at t = 1, 2, 3, and 4 h after carrageenan administration (0.1 mL of 1%,
intraplantar injection). Data are expressed as mean ± SD. Car: carrageenan 1%, CC: C. colocynthis
cream. (n = 6). * p < 0.05 vs. basal volume before carrageenan injection and # p < 0.05 vs. carrageenan
group. Repeated measures ANOVA followed by Dunnett’s test.
3.2. Effect of Topical CC Cream on Cytokines Level
As shown in Figure 2A,B, carrageenan significantly increased the TNF-α and IL-6 concentration
in the hind paw 4 h post-carrageenan injection compared with the saline group. The topical
administration of CC cream (2–8%) significantly reversed the changes in the level of TNF-α and
IL-6 due to carrageenan-induced edema, in a dose-dependent manner (p < 0.01).
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3.3. Effect of Topical CC Cream on Formalin-Induced Nociception
The injection of formalin into the hind paw produced a biphasic nociceptive response (Figure 3).
The administration of 2–8% CC cream 30 min before the formalin injection dose-dependently inhibited
both the first and the second phase of the formalin test (p < 0.05). In both phases of the formalin
test, methyl salicylate significantly inhibited pain responses and there was no significant difference
between the antinociceptive effect of methyl salicylate 30% and CC cream 8% (Figure 4A,B, p < 0.05).
The administration of naloxone (20 µg/paw, i.pl.) reversed the local antinociceptive effects of CC
cream (8%) and morphine (25 µg/paw, i.pl.) on both phases of the formalin test (Figure 5A,B, p < 0.05).
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(CC) cream in the formalin test. Naloxone (NLX, 20 µg/paw, i.pl.) was injected and then the
antinociceptive effect of morphine (MPH, 25 µg/paw, i.pl.) and CC cream (8%) was evaluated in
the first phase (A) and the second phase (B) of the formalin test. Values represent the mean ± S.D
(n = 6). * p < 0.05 vs. respective treatment. One-way ANOVA followed by Tukey’s test.
3.4. Skin Irritation Test
The result showed that the topical administration of CC cream (2–8%) did not induce any allergic
symptoms such as inflammation and irritation in rats up to seven days after application.
4. Discussion
The finding of this study revealed that the topical application of CC cream markedly suppressed
the hind paw swelling induced by carrageenan and inhibited the formalin-induced no icepti n, which
confirmed the anti-inflammatory and analgesic ctivity of this formulation. In addition, the evaluation
of the possible mechanisms suggests that the suppression of pro-inflammatory mediators and activati n
of opioid recept rs may be involved in th se effects.
Inflammation, s t ost important response of a d maged tissue which is observed i
many inflammatory disorders, is characteriz by r ness, edema, he t, and pain at the site of
inj ry [28]. During the inflammatory process, the se sitivity of nociceptors is height ned and the
threshold of pain is decreased [29]. The tissue inflamm tion is mediated by the activation and
infiltration of leukocytes into the damaged region nd the release of biochemical and pro-inflammatory
mediators, including bradykinin, prostaglandin E2 (PGE2), tumor necrosis factor-α (TNF-α),
interleukin (IL-1β), and interleukin 6 (IL-6) (6). Bradykinin, PGE2, TNF-α, and IL-1β are able to
induce hypernociceptive effects which lead to lowering the threshol for pain and are involved in
inflammatory hyperalgesia [30,31].
Carrageenan-induced pa ede a is a reproducible model that can be extensively utilized for
evaluating the anti-inflammatory activity of novel compounds. A carrageenan injection into the hind
paw induces a biphasic inflammation pattern, which in the first phase mediators such as hista ine,
leukotrienes, serotonin, cyclo xygenases, and kinins, is increased. eanwhile, in the delayed phase,
the elevation of prostaglandins, arachidonic acid metabolites, and the neutrophil influx have been
observed [24]. The effect of anti-infla atory agents is evaluated by measuring changes in paw
swelling due to the injection of carrageenan into the hind paw.
The present study is s rte a experi ents showing that an intraplantar injection
of carragee a into t e hind paw of rats induces a severe inflammatory response and results
in paw swelling [24]. However, the to ical application of CC cream clearly ameliorated paw
swelling induced by carrageenan at each time point (1, 2, 3, and 4-h post-carrageenan injectio ),
and the anti-inflammatory effect of CC 8% was comparable t that f hydrocortisone ointme t 1%.
These findings are in agreement with previous studies. Marzouk et al. (2010) showed that immature
fruit of CC aqueous extract (1 and 4 mg/kg, intraperitoneally) suppressed both phases of inflammation
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induced by a carrageenan rat model of paw edema and the maximum anti-edematous effect was at 6 h
after the carrageenan injection [10]. Also, in another study, they reported that all fractions of CC fruit
(orally), including chloroform, petroleum, ether, methanol, acetone, and ethyl acetate extract, displayed
a marked anti-inflammatory effect in an experimental model [2]. Overall, our result confirmed that the
topical administration of CC exhibited anti-edematous activity similar to systemic administration in
experimental animal models of inflammation.
Several studies have shown that an intraplantar injection of carrageenan leads to an increase in
the expression and release of various cytokines, for instance, TNF-α and IL-1β, which in turn cause
the release of further pro-inflammatory mediators, including IL-6, kinins, leukotrienes, arachidonic
acid metabolites, and reactive oxygen species [32,33]. These cytokines are the key components
of the innate immune system which activate leukocytes and provide host defenses against tissue
injuries [19,34]. The present investigation showed that paw edema induced by carrageenan was
synchronized by early elevation in TNF-α and IL-6 in hind paw tissue. Our finding indicated that
pretreatment of carrageenan-received rats either with topical cream of CC or with hydrocortisone 1%
considerably reduced the TNF-α and IL-6 levels in hind paw tissue compared to the rats treated with a
cream base. Thus, the CC cream reduced the susceptibility of rats’ paw tissue to pro-inflammatory
mediators. These findings confirm recent reports where CC downregulated these pro-inflammatory
mediators in obesity induced by a high-fat diet (HFD) [16], diabetes mellitus [5], osteoarthritis [17],
and inflammation induced by carrageenan in an animal model [2]. Akhzari et al. (2015) showed that
the expression of pro-inflammatory mediators such as TNF-α, COX-2, and INOS in chondrocyte cells
and monocytes/macrophages were reduced by treatment with an ethanol extract of CC [17]. Since the
anti-inflammatory activity of the topical administration was equal to hydrocortisone 1%, the CC cream
can be suggested as an effective agent for inflammatory disease.
In this study, the analgesic effect of the CC cream was evaluated using the formalin test in the rat.
The formalin test is a highly reproducible and common in vivo model for the evaluation of the analgesic
potential of drugs and possible mechanisms. In the rat, an intraplantar injection of formalin produces
a biphasic pain response. The first phase (0–5 min), which is called the neurogenic phase, is related to
the activation of C fibers, and the second phase (15–40 min) is due to inflammatory mechanisms and
the release of local mediators and sensitization of peripheral and spinal cord neurons [35]. Analgesics
have different effects on the formalin test due to their mechanism of action. Opioids and most NSAIDs
can inhibit both phases of the formalin test, but acetaminophen only inhibits the second phase [36].
In this study, the ipsilateral plantar application of CC cream inhibited both phases of the formalin test
in a dose-dependent manner. Morphine and methyl salicylate as reference drugs inhibited both phases
of the formalin test. The antinociceptive effect of the CC cream (8%) was comparable to that of methyl
salicylate cream 30%. However, the application of CC cream 8% (high dose) on the contralateral paw
did not inhibit the formalin-induced nociception, indicating that the CC acted peripherally at the site
of application. Our data are supported by a previous study, which showed that the oral administration
CC extract reduced the number of writhing events in acetic acid-induced writhing in mice [2,10].
Opioid receptors in the peripheral nervous system and immune cells are involved in modulating
pain and inflammation. Various behavioral studies using inflammatory models have shown
that exogenous opioids exert an antinociceptive effect by activating peripheral opioid receptors.
These receptors are expressed on small-, medium-, and large-diameter sensory neurons [37].
The activation of peripheral opioid receptors coupled to inhibitory G-proteins reduces cyclic AMP,
increases K efflux, and decreases Ca2+ entry in the sensory nerve terminals and ultimately reduces
action potential propagation and the release of excitatory neuropeptides [38]. Drugs that selectively
activate peripheral opioid receptors have therapeutic potential for pain control. Therefore, in this
study, the role of opioid receptors in the peripheral antinociceptive effect of CC was investigated.
In this study, pre-treatment with naloxone reversed the antinociceptive effect of CC in both the first
and second phases of the formalin test. It indicated that peripheral opioid receptors are involved in
the antinociceptive effect of CC and at least some of the antinociceptive effects of the CC are associated
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with the activation of opioid receptors or increased release of endogenous opioid. Furthermore, since
in the second phase of the formalin test, the analgesic effect of the extract completely was not reversed
by the naloxone, other mechanisms such as the anti-inflammatory effect are probably involved in the
peripheral antinociceptive effects of CC cream. The anti-inflammatory activity of CC has been revealed
in various animal models [5,10]. In this study, we showed that the topical application of CC cream
decreased inflammatory mediators (TNF-α and IL-6) in the carrageenan-induced paw edema model.
Since the strong analgesic and anti-inflammatory potential of flavonoids and alkaloids is well
documented [39], it seems that the antinociceptive and anti-inflammatory activity of CC cream may be
associated with its active ingredients, including flavonoids and alkaloids.
5. Conclusions
For the first time, our investigation showed that the topical of CC fruit exhibits marked
anti-inflammatory and antinociceptive activities. The anti-inflammatory and analgesic effects of CC
are significant and are comparable to steroidal anti-inflammatory agent hydrocortisone and NSAIDs,
respectively. These therapeutic benefits of CC could probably be related to the opioid receptors and its
ability to suppress the pro-inflammatory mediators. Thus, topical CC preparations are promising as a
topical anti-inflammatory and analgesic agent and have the potential application as a complementary
therapy for the treatment of inflammatory disorders. However, further pharmacological studies are
needed for their clinical application.
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